Currently browsing

septiembre 15, 2020

<em>In Vitro</em> Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

WCK 5222 (cefepime-zidebactam, 2g + 1g, q8h) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined in vitro susceptibility of 1,385 clinical isolates of carbapenem not susceptible Enterobacterales, MDR Pseudomonas aeruginosa (also carbapenem not susceptible), Stenotrophomonas maltophilia, and Burkholderia spp. collected worldwide (49 countries) during 2014-2016 to cefepime-zidebactam (1:1…